{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:08:15Z","timestamp":1769512095607,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3225002002A1"],"award-info":[{"award-number":["3225002002A1"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71704192"],"award-info":[{"award-number":["71704192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["1125000172"],"award-info":[{"award-number":["1125000172"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejim.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:06:06Z","timestamp":1683853566000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"114","author":[{"given":"Qiong","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-2265","authenticated-orcid":false,"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejim.2023.04.022_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10157-012-0746-8","article-title":"Japan renal biopsy registry and Japan kidney disease registry: committee report for 2009 and 2010","volume":"17","author":"Sugiyama","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2023.04.022_bib0002","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0003","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/ijms21010189","article-title":"A new vision of IgA nephropathy: the missing link","volume":"21","author":"Sallustio","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.ejim.2023.04.022_bib0004","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.022_bib0005","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"10.1016\/j.ejim.2023.04.022_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/nep.12629","article-title":"Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study","volume":"21","author":"Zhang","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.ejim.2023.04.022_bib0007","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.022_bib0008","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"19","key":"10.1016\/j.ejim.2023.04.022_bib0009","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ejim.2023.04.022_bib0010","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.022_bib0011","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.ejim.2023.04.022_bib0013","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.022_bib0014","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.022_bib0016","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.022_bib0017","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3349\/ymj.2011.52.4.588","article-title":"Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy","volume":"52","author":"Bang","year":"2011","journal-title":"Yonsei Med J"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"8","key":"10.1016\/j.ejim.2023.04.022_bib0019","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"10084","key":"10.1016\/j.ejim.2023.04.022_bib0020","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0021","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41598-021-03691-0","article-title":"Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","article-title":"Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial","volume":"59","author":"Liu","year":"2012","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.022_bib0023","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/0886022X.2021.1963775","article-title":"Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial","volume":"43","author":"Ni","year":"2021","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.022_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.ejim.2023.04.022_bib0025","doi-asserted-by":"crossref","first-page":"e24541","DOI":"10.1097\/MD.0000000000024541","article-title":"Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: a network meta-analysis","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.022_bib0026","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.022_bib0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"issue":"15","key":"10.1016\/j.ejim.2023.04.022_bib0028","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2023.04.022_bib0029","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ejim.2023.04.022_bib0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejim.2023.04.022_bib0031","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejim.2023.04.022_bib0032","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.ejim.2023.04.022_bib0033","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.04.022_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1041200","article-title":"Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials","volume":"9","author":"Tornyos","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ejim.2023.04.022_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.6061\/clinics\/2016(05)01","article-title":"The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China","volume":"71","author":"Huan","year":"2016","journal-title":"Clinics"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:52Z","timestamp":1760607532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"alternative-id":["S0953620523001334"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.022","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety for the treatments despite optimized renin-angiotensin system blockade among IgA nephropathy patients at high-risk of disease progression: A network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}